OBJECTIVE: To report the outcome of 124 claims of chronic
arthropathy associated with rubella vaccine submitted to the
National Vaccine Injury Compensation Program.
records and testimony were reviewed separately by physicians
andSpecial Masters to determine the clinical diagnosis and
eligibility for compensation under the Program.
the 124 subjects with chronic arthropathy, the onset occurred
between 1 week and 6 weeks after the rubella vaccination in
72,and < 1 week or > 6 weeks after the vaccination in 52.
Variousconditions developed in the 2 onset groups (1-6 weeks
postvaccination, < 1 week or > 6 weeks postvaccination),
including, respectively, unspecified arthritis (n = 29, n =
1),specified arthritis (n = 11, n = 19), arthralgia (n = 24,
n = 7),fibromyalgia (n = 4, n = 11), and multiple symptoms
with minimalarthralgia or myalgia (n = 4, n = 14).
Concordance of medicalrecommendations by Program physicians
and Special Masters'decisions in 56 completed claims was
91%, with awards mainly to patients with chronic unspecified
arthritis and arthralgia.
CONCLUSION: The Program and the US
Court of Federal Claims have accepted a causal relationship
between currently used rubella vaccine in the US and some
chronic arthropathy with an onset between 1 week and 6 weeks
after vaccine administration.
Weibel RE, Benor DE